Email this article 
Authors’ commentary on the article Clinical and economic analysis of effectiveness of Nivolumab (Opdivo®) use as second-line monotherapy in adult patients with advanced renal cell carcinoma after previous systemic therapy
- Authors: Frolov M.Y.
- Issue: Vol 13, No 2 (2017)
- Pages: 128-130
- Section: AUTHORS’ COMMENTARY
- Published: 30.06.2017
- URL: https://oncourology.abvpress.ru/oncur/article/view/691
- ID: 691
Cite item
Full Text
Abstract
2017. Vol. 13, issue1
References
Supplementary files
